http://www.medadnews.com/News/Index.cfm?articleid=572053
<p>HEIDELBERG, Germany, Sept. 18, 2008 –SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today announced that it has received a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) for AX200 in the treatment of spinal cord injury…</p>